VP, Global Marketing

Boston, MA (On-site)

$315K/yr – $395K/yrDirector/Executive15+ years expFull time

Posted 1 month ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the global commercial strategy and launch readiness for KT-621, from late-stage through lifecycle, with strong emphasis on product vision, positioning, and value proposition for immunology and atopic dermatitis markets.

  • Global Strategy & Launch: Own the end-to-end commercial plan and readiness activities across functions and geographies.
  • Messaging & Market Insight: Shape disease-state messaging and leverage analytics for competitive intelligence and forecasting inputs.
  • Cross-Functional Leadership: Align clinical development, medical affairs, market access, regulatory, finance, and leadership to drive evidence generation and expansion opportunities.

Job Description

Responsibilities

  • Lead development and execution of the global commercial strategy for KT-621 from late-stage development through launch and lifecycle management.
  • Define the global product vision, positioning, differentiation, target patient segments, and value proposition.
  • Lead global launch readiness planning and commercialization activities.
  • Develop disease-state and product-specific marketing strategies and messaging.
  • Partner closely with the Analytics & Insights function on competitive intelligence, market assessments, forecasting inputs, and customer research.
  • Serve as the commercial lead within cross-functional development teams.
  • Influence clinical development strategy, endpoint selection, and evidence-generation plans.
  • Evaluate expansion opportunities across immunology indications.
  • Build strong partnerships across Clinical Development, Medical Affairs, Market Access, Regulatory, Finance, and Executive Leadership.
Kymera Therapeutics logo

Kymera Therapeutics

4.0 Glassdoor

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Founded in 2016
Watertown, Massachusetts, USA
269 employees (5 in marketing)
71% recommend to a friend
100% CEO approval

Traffic Signals

Monthly Visitors
28.1K
Traffic Source Mix
Search
42.2%
Direct
46.8%
Referral
7.1%
Social
2%
Paid
1.5%

Headcount Trend

Current headcount: ~269

Marketing Team

Marketing Team Size
5 (2% of company)

Funding

Total Funding
$1.4B
Last Raise
Post IPO Equity, 9 months ago

Recent News